Page last updated: 2024-10-26

etodolac and Sicca Syndrome

etodolac has been researched along with Sicca Syndrome in 1 studies

Etodolac: A non-steroidal anti-inflammatory agent and cyclooxygenase-2 (COX-2) inhibitor with potent analgesic and anti-arthritic properties. It has been shown to be effective in the treatment of OSTEOARTHRITIS; RHEUMATOID ARTHRITIS; ANKYLOSING SPONDYLITIS; and in the alleviation of postoperative pain (PAIN, POSTOPERATIVE).
etodolac : A monocarboxylic acid that is acetic acid in which one of the methyl hydrogens is substituted by a 1,8-diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indol-1-yl moiety. A preferential inhibitor of cyclo-oxygenase 2 and non-steroidal anti-inflammatory, it is used for the treatment of rheumatoid arthritis and osteoarthritis, and for the alleviation of postoperative pain. Administered as the racemate, only the (S)-enantiomer is active.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Tanaka, H1
Abe, T1
Nishimura, S1
Sakai, H1
Kimura, H1
Oki, M1
Nojima, M1
Taga, M1
Matsumoto, S1
Takahashi, H1
Imai, K1

Reviews

1 review available for etodolac and Sicca Syndrome

ArticleYear
[A case of rheumatoid arthritis/Sjogren's syndrome with acute renal failure due to hyperuricemia associated with mizoribine therapy].
    Nihon Rinsho Men'eki Gakkai kaishi = Japanese journal of clinical immunology, 2004, Volume: 27, Issue:3

    Topics: Acute Kidney Injury; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Drug Therapy, C

2004